https://scientific-jl.com/luch/
Часть
-46
_ Том
-5_
июнь
-2025
165
UTERINE FIBROIDS: A CLINICAL OVERVIEW OF
PATHOGENESIS, DIAGNOSIS, AND MANAGEMENT
Kamoljonova Go’zaloy Odiljon qizi
Keywords
. Uterine fibroids, leiomyoma, benign tumours, reproductive
health, estrogen, myomectomy, non-surgical therapy,
women’s
healthy
Introduction.
Uterine fibroids, also known as leiomyomas or myomas, are
the most common benign tumours of the uterus, affecting up to 70-80% of women
during their reproductive years. These growths are composed primarily of smooth
muscle cells and varying amounts of fibrous connective tissue. Although benign
and non-metastatic, fibroids can severely impact the quality of life, fertility, and
reproductive outcomes in affected women. The burden of disease is especially
significant among women of African descent, where fibroids tend to appear earlier,
grow larger, and cause more severe symptoms.
Despite their prevalence, the exact ethology of uterine fibroids remains
incompletely understood. Genetic, hormonal, and environmental influences are all
believed to play essential roles in fibroid pathogenesis. Advances in imaging and
minimally invasive treatment options have improved diagnostic accuracy and
individualized care, but challenges remain in management, particularly when
fertility preservation is a goal. This paper provides a comprehensive overview of
the epidemiology, pathogenesis, clinical presentation, diagnostic tools, and current
treatment strategies for uterine fibroids.
Epidemiology and Risk Factors
. Uterine fibroids are particularly common
among women aged 30 to 50 years. Studies have shown that by age 50, nearly 70%
of white women and over 80% of Black women will have developed at least one
fibroid. Several risk factors have been identified:
•
Age: Prevalence increases with age, peaking before menopause.
https://scientific-jl.com/luch/
Часть
-46
_ Том
-5_
июнь
-2025
166
•
Race: Higher incidence and severity among Black women.
•
Genetic predisposition: Family history increases risk.
•
Hormonal factors: Estrogen and progesterone stimulate fibroid
growth.
•
Lifestyle factors: Obesity, early menarche, and vitamin D deficiency
are associated with increased risk.
Protective factors include higher parity, long-term use of oral contraceptives,
and smoking (which lowers estrogen levels, although it carries many other health
risks).
Pathogenesis and Molecular Biology
. Uterine fibroids originate from the
smooth muscle layer of the uterus (myometrium). Their growth is hormone-
dependent, especially influenced by estrogen and progesterone. These hormones
promote the proliferation of fibroid cells and increase extracellular matrix (ECM)
production, which contributes to fibroid size and stiffness.
Recent molecular studies have identified specific genetic mutations associated
with fibroid development, particularly in the MED12 gene, which is mutated in up
to 70% of fibroids. Other implicated factors include:
•
Dysregulated signalling pathways (e.g., TGF-, Want catenin)
•
Epigenetic changes
•
Growth factors (e.g., insulin-like growth factor, epidermal growth
factor)
•
Inflammatory cytokines and ECM dysregulation
These complex mechanisms highlight the multifactorial nature of fibroid
development and support the ongoing search for targeted therapies.
Clinical Presentation
. While many fibroids are asymptomatic and discovered
incidentally, others can cause a wide range of symptoms based on their size,
number, and location. Common clinical manifestations include:
•
Heavy or prolonged menstrual bleeding (menorrhagia)
https://scientific-jl.com/luch/
Часть
-46
_ Том
-5_
июнь
-2025
167
•
Pelvic pain or pressure
•
Urinary frequency or retention
•
Constipation
•
Infertility or recurrent pregnancy loss
Fibroids are often classified by location: submucosal, intramural, and
subserosal, each associated with different symptoms and clinical implications.
Submucosal fibroids, for example, are strongly associated with heavy bleeding and
infertility.
Treatment Strategies
. Management depends on the severity of symptoms, the
size and location of fibroids, the womanís age, and her desire for future fertility.
Treatment options are divided into medical and surgical approaches.
Medical Therapies:
•
Gonadotropin-releasing hormone (GnRH) agonists: Reduce fibroid
size temporarily by inducing a hypoestrogenic state.
•
Selective progesterone receptor modulators (SPRMs): Such as
ulipristal acetate, can control bleeding and shrink fibroids.
•
Non-hormonal options: NSAIDs for pain, tranexamic acid for
bleeding control.
Emerging Therapies and Research Directions
. New therapies under
investigation include anti-fibrotic agents, molecular inhibitors, and gene therapy.
Advances in stem cell research and targeted drug delivery may eventually
revolutionize fibroid treatment. Additionally, long-term studies on the safety and
efficacy of SPRMs and GnRH antagonists are ongoing.
Conclusion.
Uterine fibroids are a widespread gynecological condition with
a significant clinical and public health burden. Although typically benign, they can
profoundly affect a womanís reproductive health and quality of life. A
multidisciplinary approach that includes accurate diagnosis, individualized
treatment, and patient-centered counseling is essential for optimal care. Continued
https://scientific-jl.com/luch/
Часть
-46
_ Том
-5_
июнь
-2025
168
research into the molecular underpinnings of fibroids promises to improve
outcomes through targeted and less invasive therapies.
References:
1. Bulun, S. E. (2013). Uterine fibroids. The New England Journal of
Medicine, 369(14), 1344ñ1355. https://doi.org/10.1056/NEJMra1209993
2. Stewart, E. A., Laughlin-Tommaso, S. K., Catherino, W. H., Lalitkumar,
S., Gupta, D., & Vollenhoven, B. (2016). Uterine fibroids. Nature Reviews
Disease Primers, 2, 16043. https://doi.org/10.1038/nrdp.2016.43
3. Khan, A. T., Shehmar, M., & Gupta, J. K. (2014). Uterine fibroids:
current perspectives. International Journal of Womenís Health, 6, 95ñ114.
https://doi.org/10.2147/IJWH.S51083
4. Mavrelos, D., & Naftalin, J. (2022). Imaging of uterine fibroids. Best
Practice & Research Clinical Obstetrics & Gynaecology, 81, 3ñ16.
https://doi.org/10.1016/j.bpobgyn.2021.07.006
5. Peddada, S. D., Laughlin, S. K., Miner, K., Guyon, J. P., Haneke, K.,
Vahdat, H. L., Ö & Baird, D. D. (2008). Growth of uterine leiomyomata among
premenopausal black and white women. Proceedings of the National Academy of
Sciences, 105(50), 19887ñ19892
. https://doi.org/10.1073/pnas.0808188105
6. Al-Hendy, A., Myers, E. R., & Stewart, E. (2017). Uterine fibroids:
burden and unmet medical need. Seminars in Reproductive Medicine, 35(6),
473ñ480. https://doi.org/10.1055/s
-0037-1607264
7. Donnez, J., & Dolmans, M. M. (2016). Uterine fibroid management:
from the present to the future.
Human Reproduction Update, 22(6), 665ñ686.
https://doi.org/10.1093/humupd/dmw023
